Cytokinetics, Incorporated (NASDAQ:CYTK – Get Free Report)’s stock price hit a new 52-week low during mid-day trading on Monday. The stock traded as low as $53.40 and last traded at $54.08, with a volume of 207,722 shares trading hands. The stock had previously closed at $56.13.
Analyst Ratings Changes
Several analysts have issued reports on the stock. Citizens Jmp raised their price target on shares of Cytokinetics from $105.00 to $110.00 and gave the stock a “market outperform” rating in a research report on Friday, August 7th. UBS Group reaffirmed a “buy” rating and issued a $104.00 target price on shares of Cytokinetics in a research report on Wednesday, October 14th. Morgan Stanley raised Cytokinetics from an “overweight” rating to a “buy” rating in a report on Tuesday, September 1st. Weiss Ratings reissued a “sell (d-)” rating on shares of Cytokinetics in a report on Thursday, October 15th. Finally, Wall Street Zen raised Cytokinetics from a “sell” rating to a “hold” rating in a research note on Saturday, November 7th. Nineteen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Cytokinetics presently has an average rating of “Moderate Buy” and a consensus target price of $106.67.
Read Our Latest Analysis on Cytokinetics
Cytokinetics Price Performance
The firm has a market cap of $7.19 billion, a PE ratio of -8.55 and a beta of 0.45. The business’s fifty day moving average is $63.25 and its 200-day moving average is $69.65.
Cytokinetics (NASDAQ:CYTK – Get Free Report) last posted its quarterly earnings data on Wednesday, November 4th. The biopharmaceutical company reported ($1.37) EPS for the quarter, beating the consensus estimate of ($1.43) by $0.06. The firm had revenue of $47.56 million during the quarter, compared to analysts’ expectations of $41.88 million. Cytokinetics’s revenue for the quarter was up 2356.5% on a year-over-year basis. During the same quarter in the previous year, the company posted ($2.55) EPS. Analysts forecast that Cytokinetics, Incorporated will post -5.85 EPS for the current year.
Insider Buying and Selling at Cytokinetics
In related news, EVP Fady Malik sold 3,500 shares of the firm’s stock in a transaction on Tuesday, November 3rd. The stock was sold at an average price of $62.93, for a total value of $220,255.00. Following the completion of the sale, the executive vice president owned 153,902 shares of the company’s stock, valued at $9,685,052.86. This trade represents a 2.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Robert E. Landry sold 1,000 shares of the business’s stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $72.13, for a total transaction of $72,130.00. Following the transaction, the director owned 8,184 shares in the company, valued at $590,311.92. This represents a 10.89% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 174,926 shares of company stock valued at $11,942,920. 2.60% of the stock is owned by corporate insiders.
Institutional Trading of Cytokinetics
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Handelsbanken Fonder AB increased its position in Cytokinetics by 63.8% during the 2nd quarter. Handelsbanken Fonder AB now owns 405,000 shares of the biopharmaceutical company’s stock valued at $34,502,000 after purchasing an additional 157,700 shares during the period. Sanders Morris Harris LLC purchased a new position in Cytokinetics in the third quarter worth $1,549,000. Great Lakes Advisors LLC purchased a new stake in Cytokinetics in the second quarter valued at about $1,960,000. Siren L.L.C. acquired a new position in Cytokinetics during the 1st quarter valued at approximately $40,466,000. Finally, Seven Fleet Capital Management LP raised its stake in Cytokinetics by 93.0% in the 2nd quarter. Seven Fleet Capital Management LP now owns 118,240 shares of the biopharmaceutical company’s stock worth $10,073,000 after acquiring an additional 56,971 shares during the last quarter.
Cytokinetics Company Profile
Cytokinetics is a biopharmaceutical company focused on discovering and developing medicines that target the biology of muscle function. Its research centers on therapies for conditions involving impaired cardiac muscle performance. The company’s work includes aficamten, a cardiac myosin inhibitor developed for hypertrophic cardiomyopathy, and other drug candidates designed to affect muscle contraction. Cytokinetics conducts research and clinical development through programs that may involve patients and collaborators in multiple countries.
Recommended Stories
- Five stocks we like better than Cytokinetics
- AMD Bets $8.2B on Physical AI: Could Robotics Be Its Next Growth Frontier?
- 3 Stocks Flashing Buy Signals With Historical Win Rates Above 85% After the Sell-Off
- Disney Has the Magic Touch: Dividend Growth and Buybacks Could Fuel a Breakout
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with MarketBeat.com's FREE daily email newsletter.
